S41 - Neuro-oncology

Event Time: Thursday April 27, 2017 1:00 pm to 3:00 pm
Topic(s): Neuro-oncology
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:24 PM 003 Clinical and molecular characteristics of glioneuronal tumors Julie Miller, MD
Dr. Miller has nothing to disclose.

1:36 PM 004 Tumor stem cell RNA-loaded dendritic cell vaccine for recurrent glioblastoma: a phase 1 trial Anastasie Dunn-Pirio, MD
Dr. Dunn-Pirio has nothing to disclose.

1:48 PM 005 Targeting carcinoma–astrocyte gap junctions in brain metastasis Adrienne Boire, MD
Dr. Boire has nothing to disclose.

2:00 PM 006 Identification of clinically actionable PI3K pathway mutations in brain metastases from breast cancer Ugonma Chukwueke, MD
Dr. Chukwueke has nothing to disclose.

2:12 PM 007 Microtubule Associated Protein (MAP) 1B: Antigen of PCA-2 IgG, Biomarker of Small-Cell Lung Carcinoma-related Paraneoplastic Neurological Autoimmunity Avi Gadoth
,,,Mayo Foundation has applied for a patent relating to commercial testing for MAP1B autoantibody that is the subject of this report.,,,

Dr. Gadot has received royalty payments from Mayo Foundation.

2:24 PM 008 Germline genetic mutations contribute to the development of primary brain tumors: a review of a multigene panel testing cohort Amanda Bergner
Dr. Bergner has received personal compensation for activities with Ambry Genetics as an employee. Dr. Bergner has received royalty payments from UpToDate.

Ready to register for the 2018 AAN Annual Meeting?

Register Now

Related Courses